Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort

Matthew F Sidovar, Brendan L Limone, Craig I Coleman, Matthew F Sidovar, Brendan L Limone, Craig I Coleman

Abstract

Background: Mapping of patient-reported outcomes to the five-dimension EuroQol (EQ-5D) health index is increasingly being used for understanding the relationship of outcomes to health states and for predicting utilities that have application in economic evaluations. The 12-item Multiple Sclerosis Walking Scale (MSWS-12) is a patient-reported outcome that assesses the impact of walking impairment in people with MS. An equation for mapping the MSWS-12 to the EQ-5D was previously developed and validated using a North American Research Committee on MS (NARCOMS) registry cohort.

Materials and methods: This analysis retested the validity of the equation mapping the MSWS-12 to the three-level EQ-5D (EQ-5D-3L) by using an independent cohort of patients with MS enrolled in a randomized controlled trial. Mapping was evaluated at two separate time points (baseline and week 4) during the clinical trial. The mapping equation's performance was subsequently assessed with mean absolute error (MAE) and root-mean-square error (RMSE) by comparing equation-based estimates to values elicited in the trial using the actual EQ-5D-3L questionnaire.

Results: The mapping equation predicted EQ-5D-3L values in this external cohort with reasonable precision at both time points (MAE 0.116 and RMSE 0.155 at baseline; MAE 0.105 and RMSE 0.138 at week 4), and was similar to that reported in the original NARCOMS cohort (MAE 0.109 and RMSE 0.145). Also as observed in the original NARCOMS cohort, the mapping equation performed best in patients with EQ-5D-3L values between 0.50 and 0.75, and poorly in patients with values <0.50.

Conclusion: The mapping equation performed similarly in this external cohort as in the original derivation cohort, including a poorer performance in MS patients with more severe health-state severity.

Keywords: EQ-5D-3L; MSWS-12; health status index; health-related quality of life; mapping.

Figures

Figure 1
Figure 1
Scatterplot of observed versus predicted EQ-5D-3L scores for the DER-401 cohort at baseline. Note: Data points lying closest to the diagonal line (representing the line of perfect fit) illustrate more precise estimates of observed EQ-5D-3L scores. Abbreviations: DER, dalfampridine extended release; EQ-5D-3L, EuroQol 5-dimension 3-level version.
Figure 2
Figure 2
Scatterplot of observed versus predicted EQ-5D-3L scores for the DER-401 cohort at week 4. Note: Data points lying closest to the diagonal line (representing the line of perfect fit) illustrate more precise estimates of observed EQ-5D-3L scores. Abbreviations: DER, dalfampridine extended release; EQ-5D-3L, EuroQol 5-dimension 3-level version.

References

    1. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12) Neurology. 2003;60(1):31–36.
    1. Waxman SG. Conduction in myelinated, unmyelinated, and demyelinated fibers. Arch Neurol. 1977;34(10):585–589.
    1. Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci. 1999;354(1390):1649–1673.
    1. Sutliff M. Contribution of impaired mobility to patient burden in multiple sclerosis. Curr Med Res Opin. 2010;26(1):109–119.
    1. Salter AR, Cutter GR, Tyry T, Marrie RA, Vollmer T. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin. 2010;26(2):493–500.
    1. LaRocca N. Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient. 2011;4(3):189–201.
    1. Dakin H. Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database. Health Qual Life Outcomes. 2013;11:151.
    1. EuroQol Group EuroQol – a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.
    1. Sidovar MF, Limone BL, Lee S, Coleman CI. Mapping the 12-item multiple sclerosis walking scale to the EuroQol 5-dimension index measure in North American multiple sclerosis patients. BMJ Open. 2013;3(5):e002798.
    1. Yapundich R, Applebee A, Bethoux F, et al. Evaluation of dalfampridine extended release 5 and 10 mg in MS; a randomized, controlled trial. Int J MS Care. 2015;17(3):138–145.
    1. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72.
    1. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43(3):203–220.
    1. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12) Neurology. 2003;60(1):31–36.
    1. Longworth L, Rowen D, National Institute for Health and Clinical Excellence (NICE) Decision Support Unit (DSU) Technical Support Document 10: The use of mapping methods to estimate health state utility values. [Accessed September 5, 2015]. Available from: .
    1. Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes. 2009;7:27.
    1. Hawton A, Green C, Telford C, Wright D, Zajicek J. The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D. Mult Scler. 2012;18(6):853–861.
    1. Limone BL, Sidovar MF, Coleman CI. Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients. Health Qual Life Outcomes. 2013;11:105.
    1. Hobart J, Cano S, Ingram W, Zajicek J. A new path for the MS Walking Scale: MSWS-12 version 2. Mult Scler. 2012;18(4):334–335.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren